|  |
| --- |
|  |
| Book Name: | [**Disease and Health: Research Developments**](https://www.bookpi.org/bookstore/product/disease-and-health-research-developments-vol-1/) |
| Manuscript Number: | **Ms\_BPR\_4833** |
| Title of the Manuscript:  | **Neuroprotective effects of natural plant extracts in Parkinson’s Disease Models: A meta-analysis** |
| Type of the Article | **Book Chapter** |

**Special note:**

**A research paper already published in a journal can be published as a Book Chapter in an expanded form with proper copyright approval.**

**Source Article:**

**This chapter is an extended version of the article published by the same author(s) in the following journal.**

**African Journal of Biomedical Research, 27(3): 643-650, 2024.**

**DOI:** [**https://doi.org/10.53555/AJBR.v27i3.2623**](https://doi.org/10.53555/AJBR.v27i3.2623)

|  |
| --- |
| PART 1: Comments |
|  | Reviewer’s comment**Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer review.** | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | This publication is highly valuable for the scientific community as it provides a complete meta-analysis of the neuroprotective benefits of natural plant extracts in Parkinson’s disease (PD) models. By focusing on Ginkgo biloba, Curcuma longa, and Withania somnifera, the study shows their antioxidant, anti-inflammatory, and neurotransmitter-modulating characteristics, which are critical for neuroprotection. The findings not only reaffirm the therapeutic potential of these natural extracts but also underline the issues relating to bioavailability and standardization that must be addressed before clinical translation. Ultimately, this work serves as a framework for future research, underlining the critical need for clinical studies to test the usefulness of these chemicals in human populations. |  |
| **Is the title of the article suitable?****(If not please suggest an alternative title)** | **Yes** |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | **Yes** |  |
| **Is the manuscript scientifically, correct? Please write here.**  | **Correct** |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.****-** | **Include more recent references, remove very old references****Cite the below mentioned references****-** Role of phytotherapy in diabetic neuropathy and neurodegeneration: from pathogenesis to treatment- Atorvastatin's Reduction of Alzheimer's Disease and Possible Alteration of Cognitive Function in Midlife as well as its Treatment- Assessing drug utilization and drug–drug interactions in the management of epilepsy, Alzheimer’s, Parkinson’s disease and migraine- Mathematical modelling of Alzheimer’s disease biomarkers: Targeting Amyloid beta, Tau protein, Apolipoprotein E and Apoptotic pathways- Neuroprotective effects of Bauhinia variegata in ameliorating diabetic neuropathy and neurodegeneration |  |
| Is the language/English quality of the article suitable for scholarly communications? | Suitable language used, modify grammer changes in whole manuscript once |  |
| Optional/General comments |  |  |

|  |
| --- |
| **PART 2:**  |
|  | Reviewer’s comment | Author’s comment *(if agreed with the reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?**  | *(If yes, Kindly please write down the ethical issues here in detail)* |  |

**Reviewer details:**

**Nilay Solanki, CHARUSAT, India**